UCMOK
STAB

United Capital Management of KS’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

United Capital Management of KS’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,000
Closed -$1.22K – 92
2022
Q4 		$1.22K Hold
15,000
– – ﹤0.01% 84
2022
Q3 		$2K Hold
15,000
– – ﹤0.01% 86
2022
Q2 		$4K Buy
+15,000
New +$3.88K ﹤0.01% 85

Other funds holding STAB

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TAM
Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

United Capital Management of KS's STAB Position: Q1 2023 in Review

United Capital Management of KS sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 15,000 shares — an estimated $1.22K sold.

United Capital Management of KS first reported a position in STAB in Q2 2022 and held it in 3 quarters. The position peaked at $4K in Q2 2022. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

  • United Capital Management of KS reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • United Capital Management of KS sold 15,000 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $1.22K.
  • United Capital Management of KS first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • United Capital Management of KS's Statera Biopharma, Inc. Common Stock position peaked at $4K in Q2 2022.
  • 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on United Capital Management of KS's 13F filing for Q1 2023, filed 27 Apr 2023.